A Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy

Trial Profile

A Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
    • 25 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
    • 22 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top